The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Experimental study of iodine-131 labeling of a novel tumor-targeting peptide, TFMP-Y4, in the treatment of hepatocellular carcinoma with internal irradiation.
OBJECTIVE: To explore and compare the value of I-TFMP-Y4 and I-Caerin 1.1 in internal irradiation therapy for hepatocellular carcinoma.
METHODS: (1) 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) analysis revealed the inhibitory effects of Caerin 1.1 and TFMP-Y4 on Hepg2 and LO2 cell growth. (2) The chloramine-T method was used to prepare I-Caerin 1.1 and I-TFMP-Y4. (3) Uptake and elution assays revealed that Hepg2 cells bound and retained I-Caerin 1.1 and I-TFMP-Y4, and the inhibitory effects on Hepg2 cells were verified with cellular proliferation/toxicity assays. (4) A hormonal nude mouse model was established to study the in vivo therapeutic effects of the peptides alone, I-Caerin 1.1 and I-TFMP-Y4.
RESULTS: (1) Caerin 1.1 inhibited Hepg2 and LO2 cell proliferation in a concentration-dependent manner, and the half-maximal inhibitory concentrations (IC) were 9.34 µg/mL and 22.16 µg/mL, respectively. Moreover, TFMP-Y4 did not inhibit these two cell lines. (2) The labeling rates of I-Caerin 1.1 and I-TFMP-Y4 were high and stable. Both could significantly reduce the activity of Hepg2 cells and inhibit tumor growth in vitro and in vivo.
CONCLUSION: I-Caerin 1.1 and I-TFMP-Y4 significantly inhibited the proliferation of Hepg2 cells in vitro and in vivo. In addition, I-TFMP-Y4 can reduce adverse reactions during treatment.
Stay Informed!
